Lupin Ltd

Pharmaceutical giant Lupin Ltd has announced the launch of its Ipratropium Bromide nasal spray in the U.S. market, offering two strengths—0.03% and 0.06%—to treat runny nose symptoms linked to allergic and nonallergic rhinitis as well as the common cold. The formulations are bioequivalent to Boehringer Ingelheim’s Atrovent nasal spray, which reported annual sales of approximately USD 63 million as of May 2025.

Lupin Ltd., a leading pharmaceutical player, has announced the commercial launch of its generic Tolvaptan tablets in the United States, targeting patients with autosomal dominant polycystic kidney disease (ADPKD). Following a regulatory nod from the U.S. Food and Drug Administration (USFDA), Lupin now holds the coveted 180-day exclusivity window for this therapy, positioning the company advantageously in a high-value therapeutic segment.

Lupin Ltd, a leading pharmaceutical company, has received approval from the US Food and Drug Administration (USFDA) for its generic version of Tolvaptan tablets. This drug, which is indicated for autosomal dominant polycystic kidney disease (ADPKD), will be available in multiple strengths. The approval marks Lupin's significant move into the nephrology market and positions the company as an exclusive first-to-file manufacturer, eligible for 180 days of market exclusivity.